Annual Alzheimer's Clinical Trials Pipeline Report Shows Increased Reason for Optimism

Hope Rises As More Alzheimer’s Drugs Enter Clinical Trials

Share Post Share Email There are more potential new medicines being tested for Alzheimer’s disease, according to an annual review published today, which reports that 138 drugs are currently being tested – an increase of nearly 9% from last year. Drugs that could potentially help people in all stages of Alzheimer’s are being tested, from those in people showing no symptoms to those in later stages and with sever…

Annual Alzheimer's Clinical Trials Pipeline Report Shows Increased Reason for Optimism

An annual review of clinical trials for Alzheimer's disease highlights a growing number of active trials - and drugs - in the development pipeline and offers optimism for the global effort to find a cure. The annual Alzheimer's disease drug development pipeline report is led by Dr. Jeffrey Cummings, a renowned Alzheimer's clinician-scientist.